In a study of patients with episodic and chronic migraine who experienced 2-4 prior preventive category failures,
The safety profile of Emgality in the CONQUER study was consistent with the safety profile observed in 4 clinical trials1-3
TEAEsa Over Months 1 to 3
TEAE | Emgality 120 mg (n=232) | Placebo (n=230) |
Any Injection Site Related Adverse Eventb | 7% | 10% |
- 1 patient on Emgality discontinued due to an adverse event considered indicative of hypersensitivity. There were no clinically meaningful differences in laboratory parameters, vital signs, weight, or ECG parameters between treatment groups1
See study design for CONQUER.
Lilly continues to monitor the safety data of Emgality in the general population.
See safety data for EVOLVE-1 and 2, REGAIN, and episodic cluster headache.
SELECT IMPORTANT SAFETY INFORMATION
Contraindications
Emgality is contraindicated in patients with serious hypersensitivity to galcanezumab-gnlm or to any of the excipients.
References
- Mulleners WM, Kim BK, Láinez MJA, et al. Safety and efficacy of galcanezumab in patients for whom previous migraine preventive medication from two to four categories had failed (CONQUER): a multicentre, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2020;19(10):814-825.
- Emgality. Prescribing information. Lilly USA, LLC.
- Bangs ME, Kudrow D, Wang S, et al. Safety and tolerability of monthly galcanezumab injections in patients with migraine: integrated results from migraine clinical studies. BMC Neurol. 2020;20:90.